Similar to TILs, PD-L1 expression has been found to be a prognostic marker in breast cancer, with studies demonstrating an association between PD-L1 expression and improved prognosis in TNBC but not HR+ breast cancer (25, 136–138). Here, CD274 is linked to breast cancer.